Met Life Investment Management, LLC 89bio, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 50,265 shares of ETNB stock, worth $550,401. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,265
Previous 45,232
11.13%
Holding current value
$550,401
Previous $334,000
15.27%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ETNB
# of Institutions
172Shares Held
125MCall Options Held
78.7KPut Options Held
979K-
Janus Henderson Group PLC London, X016.5MShares$181 Million0.07% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$155 Million1.76% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.2MShares$112 Million3.26% of portfolio
-
Rtw Investments, LP New York, NY7.48MShares$81.9 Million0.94% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$76.8 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $509M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...